Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

____________________________________________________________________________________________________________________________________

FORM 10-Q

____________________________________________________________________________________________________________________________________

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended January 1, 2022

☐	TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-14423

____________________________________________________________________________________________________________________________________

PLEXUS CORP.

(Exact name of registrant as specified in charter)

____________________________________________________________________________________________________________________________________

Wisconsin	39-1344447
(State or other jurisdiction of incorporation)	(I.R.S. Employer Identification No.)

One Plexus Way

Neenah, Wisconsin 54957

(Address of principal executive offices) (Zip Code)

Telephone Number (920) 969-6000

(Registrant’s telephone number, including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.01 par value	PLXS	The Nasdaq Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x	Accelerated filer	☐	Non-accelerated filer	☐
Smaller reporting company	☐	Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of February 1, 2022, there were 28,096,789 shares of common stock outstanding.

Table of Contents

PLEXUS CORP.

January 1, 2022

PART I. FINANCIAL INFORMATION	3
ITEM 1. FINANCIAL STATEMENTS	3
Condensed Consolidated Statements of Comprehensive Income	3
Condensed Consolidated Balance Sheets	4
Condensed Consolidated Statements of Shareholders' Equity	5
CondensedConsolidatedStatementsof Cash Flows	6
Notes to Condensed Consolidated Financial Statements	7
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	18
"Safe Harbor" Cautionary Statement Under the Private Securities Litigation Reform Act of 1995	18
Overview	18
Results of Operations	21
Liquidity of Capital Resources	24
Disclosure About Critical Accounting Policies	29
New Accounting Pronouncements	29
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	29
ITEM 4. CONTROLS AND PROCEDURES	30
PART II. OTHER INFORMATION	30
ITEM 1A. Risk Factors	30
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds	30
ITEM 6. Exhibits	31
SIGNATURES	32

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PLEXUS CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands, except per share data)

Unaudited

	Three Months Ended
	January 1, 2022		January 2, 2021
Net sales	$	817,456	$	830,355
Cost of sales	747,460		751,078
Gross profit	69,996		79,277
Selling and administrative expenses	37,502		32,411
Restructuring and impairment charges	2,021		—
Operating income	30,473		46,866
Other income (expense):
Interest expense	(3,046)		(4,086)
Interest income	271		374
Miscellaneous, net	(923)		(1,518)
Income before income taxes	26,775		41,636
Income tax expense	3,352		5,437
Net income	$	23,423	$	36,199
Earnings per share:
Basic	$	0.84	$	1.25
Diluted	$	0.82	$	1.23
Weighted average shares outstanding:
Basic	28,018		28,861
Diluted	28,709		29,539
Comprehensive income:
Net income	$	23,423	$	36,199
Other comprehensive (loss) income:
Derivative instrument and other fair value adjustments	1,272		4,055
Foreign currency translation adjustments	(1,578)		8,700
Other comprehensive (loss) income	(306)		12,755
Total comprehensive income	$	23,117	$	48,954

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

PLEXUS CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except per share data)

Unaudited

	January 1, 2022		October 2, 2021
ASSETS
Current assets:
Cash and cash equivalents	$	217,067	$	270,172
Restricted cash	1,324		341
Accounts receivable, net of allowances of $1,753 and $1,188, respectively	589,253		519,684
Contract assets	105,450		115,283
Inventories, net	1,185,915		972,312
Prepaid expenses and other	62,470		53,094
Total current assets	2,161,479		1,930,886
Property, plant and equipment, net	414,981		395,094
Operating lease right-of-use assets	69,519		72,087
Deferred income taxes	27,346		27,385
Other assets	36,321		36,441
Total non-current assets	548,167		531,007
Total assets	$	2,709,646	$	2,461,893
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term debt and finance lease obligations	$	151,417	$	66,313
Accounts payable	711,248		634,969
Customer deposits	265,759		204,985
Accrued salaries and wages	57,221		75,394
Other accrued liabilities	180,840		147,042
Total current liabilities	1,366,485		1,128,703
Long-term debt and finance lease obligations, net of current portion	187,075		187,033
Long-term accrued income taxes payable	47,974		47,974
Long-term operating lease liabilities	36,343		37,970
Deferred income taxes payable	5,307		5,677
Other liabilities	22,367		26,304
Total non-current liabilities	299,066		304,958
Total liabilities	1,665,551		1,433,661
Commitments and contingencies
Shareholders’ equity:
Preferred stock, $0.01 par value, 5,000 shares authorized, none issued or outstanding	—		—
Common stock, $0.01 par value, 200,000 shares authorized, 53,909 and 53,849 shares issued, respectively, and 27,997 and 28,047 shares outstanding, respectively	539		538
Additional paid-in capital	642,654		639,778
Common stock held in treasury, at cost, 25,912 and 25,802 shares, respectively	(1,053,222)		(1,043,091)
Retained earnings	1,457,414		1,433,991
Accumulated other comprehensive loss	(3,290)		(2,984)
Total shareholders’ equity	1,044,095		1,028,232
Total liabilities and shareholders’ equity	$	2,709,646	$	2,461,893

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

PLEXUS CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(in thousands)

Unaudited

	Three Months Ended
	January 1, 2022		January 2, 2021
Common stock - shares outstanding
Beginning of period	28,047		29,002
Exercise of stock options and vesting of other share-based awards	60		71
Treasury shares purchased	(110)		(307)
End of period	27,997		28,766
Total stockholders' equity, beginning of period	$	1,028,232	$	977,480
Common stock - par value
Beginning of period	538		535
Exercise of stock options and vesting of other share-based awards	1		1
End of period	539		536
Additional paid-in capital
Beginning of period	639,778		621,564
Share-based compensation expense	6,270		5,349
Exercise of stock options and vesting of other share-based awards, including tax withholding	(3,394)		(2,054)
End of period	642,654		624,859
Treasury stock
Beginning of period	(1,043,091)		(934,639)
Treasury shares purchased	(10,131)		(22,771)
End of period	(1,053,222)		(957,410)
Retained earnings
Beginning of period	1,433,991		1,295,079
Net income	23,423		36,199
End of period	1,457,414		1,331,278
Accumulated other comprehensive (loss) income
Beginning of period	(2,984)		(5,059)
Other comprehensive (loss) income	(306)		12,755
End of period	(3,290)		7,696
Total stockholders' equity, end of period	$	1,044,095	$	1,006,959

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

PLEXUS CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

Unaudited

	Three Months Ended
	January 1, 2022		January 2, 2021
Cash flows from operating activities
Net income	$	23,423	$	36,199
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	15,489		14,836
Deferred income taxes	35		366
Share-based compensation expense and related charges	6,357		5,349
Provision for allowance for doubtful accounts	—		(2,346)
Other, net	567		754
Changes in operating assets and liabilities, excluding impacts of acquisition:
Accounts receivable	(70,159)		3,585
Contract assets	9,904		866
Inventories	(214,416)		3,710
Other current and non-current assets	(9,436)		(7,561)
Accrued income taxes payable	1,121		3,277
Accounts payable	76,222		(23,514)
Customer deposits	60,743		(5,016)
Other current and non-current liabilities	11,171		(23,789)
Cash flows (used in) provided by operating activities	(88,979)		6,716
Cash flows from investing activities
Payments for property, plant and equipment	(33,246)		(15,880)
Other, net	(124)		113
Cash flows used in investing activities	(33,370)		(15,767)
Cash flows from financing activities
Borrowings under debt agreements	181,134		4,177
Payments on debt and finance lease obligations	(97,565)		(4,175)
Repurchases of common stock	(10,131)		(22,771)
Proceeds from exercise of stock options	307		722
Payments related to tax withholding for share-based compensation	(3,702)		(2,775)
Cash flows provided by (used in) financing activities	70,043		(24,822)
Effect of exchange rate changes on cash and cash equivalents	184		2,912
Net decrease in cash and cash equivalents and restricted cash	(52,122)		(30,961)
Cash and cash equivalents and restricted cash:
Beginning of period	270,513		387,894
End of period	$	218,391	$	356,933

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

PLEXUS CORP. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JANUARY 1, 2022 AND JANUARY 2, 2021

Unaudited

1. Basis of Presentation

Basis of Presentation:

The accompanying Condensed Consolidated Financial Statements included herein have been prepared by Plexus Corp. and its subsidiaries (together “Plexus” or the “Company”) without audit and pursuant to the rules and regulations of the United States (“U.S.”) Securities and Exchange Commission (“SEC”). The accompanying Condensed Consolidated Financial Statements reflect all adjustments, which include normal recurring adjustments necessary for the fair statement of the condensed consolidated financial position of the Company as of January 1, 2022 and October 2, 2021, the results of operations and shareholders' equity for the three months ended January 1, 2022 and January 2, 2021, and the cash flows for the same three month periods.

The Company’s fiscal year ends on the Saturday closest to September 30. The Company uses a “4-4-5” weekly accounting system for the interim periods in each quarter. Each quarter, therefore, ends on a Saturday at the end of the 4-4-5 period. Periodically, an additional week must be added to the fiscal year to re-align with the Saturday closest to September 30. All fiscal quarters presented herein included 13 weeks.

Certain information and footnote disclosures, normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"), have been condensed or omitted pursuant to the SEC’s rules and regulations dealing with interim financial statements. However, the Company believes that the disclosures made in the Condensed Consolidated Financial Statements included herein are adequate to make the information presented not misleading. It is suggested that these Condensed Consolidated Financial Statements be read in conjunction with the Consolidated Financial Statements and notes thereto included in the Company’s 2021 Annual Report on Form 10-K.

The preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and notes thereto. The full extent to which the COVID-19 outbreak will impact the Company's business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted. The Company has considered information available as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision of the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.

Recently Issued Accounting Pronouncements Not Yet Adopted:

The Company believes that no recently issued accounting standards will have a material impact on its Consolidated Financial Statements, or apply to its operations.

2. Inventories

Inventories as of January 1, 2022 and October 2, 2021 consisted of the following (in thousands):

	January 1, 2022		October 2, 2021
Raw materials	$	1,051,889	$	860,538
Work-in-process	57,381		48,356
Finished goods	76,645		63,418
Total inventories, net	$	1,185,915	$	972,312

In certain circumstances, per contractual terms, customer deposits are received by the Company to offset inventory risks. The total amount of customer deposits related to inventory and included within current liabilities on the accompanying Condensed Consolidated Balance Sheets as of January 1, 2022 and October 2, 2021 were $260.3 million and $200.6 million, respectively.

Table of Contents

3. Debt, Finance Lease Obligations and Other Financing

Debt and finance lease obligations as of January 1, 2022 and October 2, 2021, consisted of the following (in thousands):

	January 1, 2022		October 2, 2021
4.05% Senior Notes, due June 15, 2025	$	100,000	$	100,000
4.22% Senior Notes, due June 15, 2028	50,000		50,000
Borrowings under the revolving commitment	140,000		55,000
Finance lease and other financing obligations	49,353		49,279
Unamortized deferred financing fees	(861)		(933)
Total obligations	338,492		253,346
Less: current portion	(151,417)		(66,313)
Long-term debt and finance lease obligations, net of current portion	$	187,075	$	187,033

On June 15, 2018, the Company entered into a Note Purchase Agreement (the “2018 NPA”) pursuant to which it issued an aggregate of $150.0 million in principal amount of unsecured senior notes, consisting of $100.0 million in principal amount of 4.05% Series A Senior Notes, due on June 15, 2025, and $50.0 million in principal amount of 4.22% Series B Senior Notes, due on June 15, 2028 (collectively, the “2018 Notes”), in a private placement. The 2018 NPA includes customary operational and financial covenants with which the Company is required to comply, including, among others, maintenance of certain financial ratios such as a total leverage ratio and a minimum interest coverage ratio. The 2018 Notes may be prepaid in whole or in part at any time, subject to payment of a make-whole amount; interest on the 2018 Notes is payable semiannually. As of January 1, 2022, the Company was in compliance with the covenants under the 2018 NPA.

On May 15, 2019, the Company refinanced its then-existing senior unsecured revolving credit facility by entering into a new 5-year senior unsecured revolving credit facility (referred to as the "Credit Facility"), which expanded the maximum commitment from $300.0 million to $350.0 million and extended the maturity from July 5, 2021 to May 15, 2024. The maximum commitment under the Credit Facility may be further increased to $600.0 million, generally by mutual agreement of the Company and the lenders, subject to certain customary conditions. During the three months ended January 1, 2022, the highest daily borrowing was $186.0 million; the average daily borrowings were $117.9 million. The Company borrowed $181.0 million and repaid $96.0 million of revolving borrowings ("revolving commitment") under the Credit Facility during the three months ended January 1, 2022. As of January 1, 2022, the Company was in compliance with all financial covenants relating to the Credit Facility, which are generally consistent with those in the 2018 NPA discussed above. The Company is required to pay a commitment fee on the daily unused revolving commitment based on the Company's leverage ratio; the fee was 0.125% as of January 1, 2022.

The fair value of the Company’s debt, excluding finance lease and other financing obligations, was $298.9 million and $217.1 million as of January 1, 2022 and October 2, 2021, respectively. The carrying value of the Company's debt, excluding finance lease and other financing obligations, was $290.0 million and $205.0 million as of January 1, 2022 and October 2, 2021, respectively. If measured at fair value in the financial statements, the Company's debt would be classified as Level 2 in the fair value hierarchy. Refer to Note 4, "Derivatives and Fair Value Measurements," for further information regarding the Company's fair value calculations and classifications.

4. Derivatives and Fair Value Measurements

All derivatives are recognized in the accompanying Condensed Consolidated Balance Sheets at their estimated fair value. The Company uses derivatives to manage the variability of foreign currency obligations. The Company has cash flow hedges related to forecasted foreign currency obligations, in addition to non-designated hedges to manage foreign currency exposures associated with certain foreign currency denominated assets and liabilities. The Company does not enter into derivatives for speculative purposes.

Table of Contents

The Company designates some foreign currency exchange contracts as cash flow hedges of forecasted foreign currency expenses. Changes in the fair value of the derivatives that qualify as cash flow hedges are recorded in "Accumulated other comprehensive loss" in the accompanying Condensed Consolidated Balance Sheets until earnings are affected by the variability of the cash flows. In the next twelve months, the Company estimates that $0.2 million of unrealized gains, net of tax, related to cash flow hedges will be reclassified from other comprehensive (loss) income into earnings. Changes in the fair value of the non-designated derivatives related to recognized foreign currency denominated assets and liabilities are recorded in "Miscellaneous, net" in the accompanying Condensed Consolidated Statements of Comprehensive Income.

The Company enters into forward currency exchange contracts for its operations in Malaysia and Mexico on a rolling basis. The Company had cash flow hedges outstanding with a notional value of $117.9 million as of January 1, 2022, and a notional value of $107.4 million as of October 2, 2021. These forward currency contracts fix the exchange rates for the settlement of future foreign currency obligations that have yet to be realized. The total fair value of the forward currency exchange contracts was a $0.2 million asset as of January 1, 2022, and a $1.0 million liability as of October 2, 2021.

The Company had additional forward currency exchange contracts outstanding as of January 1, 2022, with a notional value of $32.3 million; there were $38.6 million such contracts outstanding as of October 2, 2021. The Company did not designate these derivative instruments as hedging instruments. The net settlement amount (fair value) related to these contracts is recorded on the Condensed Consolidated Balance Sheets as either a current or long-term asset or liability, depending on the term, and as an element of "Miscellaneous, net" in the Condensed Consolidated Statements of Comprehensive income. The total fair value of these derivatives was a $0.1 million asset as of January 1, 2022, and a $0.2 million liability as of October 2, 2021.

The tables below present information regarding the fair values of derivative instruments (as defined in Note 1, "Description of Business and Significant Accounting Policies") and the effects of derivative instruments on the Company’s Condensed Consolidated Financial Statements:

Fair Values of Derivative Instruments (in thousands)
	Derivative Assets					Derivative Liabilities
		January 1,<br>2022		October 2,<br>2021			January 1,<br>2022		October 2,<br>2021
Derivatives designated as hedging instruments	Balance sheet<br>classification	Fair Value		Fair Value		Balance sheet<br>classification	Fair Value		Fair Value
Foreign currency forward contracts	Prepaid expenses and other	$	356	$	76	Other accrued liabilities	$	127	$	1,119	Fair Values of Derivative Instruments (in thousands)
---	---	---	---	---	---	---	---	---	---	---
	Derivative Assets					Derivative Liabilities
		January 1,<br>2022		October 2,<br>2021			January 1,<br>2022		October 2,<br>2021
Derivatives not designated as hedging instruments	Balance sheet<br>classification	Fair Value		Fair Value		Balance sheet<br>classification	Fair Value		Fair Value
Foreign currency forward contracts	Prepaid expenses and other	$	176	$	133	Other accrued liabilities	$	112	$	356	The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Loss ("OCL") (in thousands)
---	---	---	---	---	---	---
for the Three Months Ended
Derivatives in cash flow hedging relationships		Amount of Gain Recognized in OCL on Derivatives
	January 1, 2022			January 2, 2021
Foreign currency forward contracts		$	470		$	4,159		Derivative Impact on Gain (Loss) Recognized in Condensed Consolidated Statements of Comprehensive Income (in thousands)
---	---	---	---	---	---	---	---
for the Three Months Ended
Derivatives in cash flow hedging relationships	Classification of (Loss) Gain Reclassified from Accumulated OCL into Income		Amount of (Loss) Gain Reclassified from Accumulated OCL into Income
		January 1, 2022			January 2, 2021
Foreign currency forward contracts	Cost of sales		$	(743)		$	98
Foreign currency forward contracts	Selling and administrative expenses		$	(59)		$	6

Table of Contents

Derivatives not designated as hedging instruments	Location of (Loss) Gain Recognized on Derivatives in Income		Amount of (Loss) Gain on Derivatives Recognized in Income
		January 1, 2022			January 2, 2021
Foreign currency forward contracts	Miscellaneous, net		$	(43)		$	530

Fair Value Measurements:

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (or exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses quoted market prices when available or discounted cash flows to calculate fair value. The accounting guidance establishes a fair value hierarchy based on three levels of inputs that may be used to measure fair value. The input levels are:

Level 1: Quoted (observable) market prices in active markets for identical assets or liabilities.

Level 2: Inputs other than Level 1 that are observable, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the asset or liability.

The following table lists the fair values of assets of the Company’s derivatives as of January 1, 2022 and October 2, 2021, by input level:

Fair Value Measurements Using Input Levels Asset/(Liability) (in thousands)
Fiscal year ended January 1, 2022	Level 1		Level 2		Level 3		Total
Derivatives
Foreign currency forward contracts	$	—	$	293	$	—	$	293
Fiscal year ended October 2, 2021
Derivatives
Foreign currency forward contracts	$	—	$	(1,266)	$	—	$	(1,266)

The fair value of foreign currency forward contracts is determined using a market approach, which includes obtaining directly or indirectly observable values from third parties active in the relevant markets. Inputs in the fair value of the foreign currency forward contracts include prevailing forward and spot prices for currency.

5. Income Taxes

Income tax expense for the three months ended January 1, 2022 was $3.4 million compared to $5.4 million for the three months ended January 2, 2021.

The effective tax rates for the three months ended January 1, 2022 and January 2, 2021 were 12.5% and 13.1%, respectively. The effective tax rate for the three months ended January 1, 2022 decreased from the effective tax rate for the three months ended January 2, 2021 primarily due to additional discrete tax benefits of $0.6 million partially offset by a change in the geographic distribution of pre-tax book income.

The amount of unrecognized tax benefits recorded for uncertain tax positions increased by $0.5 million for the three months ended January 1, 2022. The Company recognizes accrued interest and penalties on uncertain tax positions as a component of income tax expense. The amount of interest and penalties recorded for the three months ended January 1, 2022 was not material.

Table of Contents

One or more uncertain tax positions may be settled within the next 12 months. Settlement of these matters is not expected to have a material effect on the Company's consolidated results of operations, financial position and cash flows. The Company is not currently under examination by taxing authorities in the U.S. The Company is under audit in a foreign jurisdiction but a settlement is not expected to have a material impact.

The Company maintains valuation allowances when it is more likely than not that all or a portion of a net deferred tax asset will not be realized. During the three months ended January 1, 2022, the Company continued to record a full valuation allowance against its net deferred tax assets in certain jurisdictions within the EMEA segment and a partial valuation against its net deferred tax assets in certain jurisdictions within the AMER segment, as it was more likely than not that these assets would not be fully realized based primarily on historical performance. The Company will continue to provide a valuation allowance against its net deferred tax assets in each of the applicable jurisdictions going forward until it determines it is more likely than not that the deferred tax assets will be realized.

6. Earnings Per Share

The following is a reconciliation of the amounts utilized in the computation of basic and diluted earnings per share for the three months ended January 1, 2022 and January 2, 2021 (in thousands, except per share amounts):

	Three Months Ended
	January 1, 2022		January 2, 2021
Net income	$	23,423	$	36,199
Basic weighted average common shares outstanding	28,018		28,861
Dilutive effect of share-based awards and options outstanding	691		678
Diluted weighted average shares outstanding	28,709		29,539
Earnings per share:
Basic	$	0.84	$	1.25
Diluted	$	0.82	$	1.23

For the three months ended January 1, 2022 and January 2, 2021, there were no antidilutive awards.

See also Note 12, "Shareholders' Equity," for information regarding the Company's share repurchase plans.

7. Leases

The components of lease expense for the three months ended January 1, 2022 and January 2, 2021 were as follows (in thousands):

	Three Months Ended
	January 1, 2022		January 2, 2021
Finance lease expense:
Amortization of right-of-use assets	$	1,693	$	1,016
Interest on lease liabilities	1,222		1,203
Operating lease expense	2,857		2,752
Other lease expense	1,404		1,253
Total	$	7,176	$	6,224

Based on the nature of the right-of-use ("ROU") asset, amortization of finance lease ROU assets, operating lease expense and other lease expense are recorded within either cost of goods sold or selling and administrative expenses and interest on finance lease liabilities is recorded within interest expense on the Condensed Consolidated Statements of Comprehensive Income. Other lease expense includes lease expense for leases with an estimated total term of twelve months or less and variable lease expense related to variations in lease payments as a result of a change in factors or circumstances occurring after the lease possession date.

Table of Contents

The following tables sets forth the amount of lease assets and lease liabilities included in the Company’s Condensed Consolidated Balance Sheets (in thousands):

	Financial Statement Line Item	January 1, 2022		October 2, 2021
ASSETS
Finance lease assets	Property, plant and equipment, net	$	38,842	$	38,657
Operating lease assets	Operating lease right-of-use assets	69,519		72,087
Total lease assets		$	108,361	$	110,744
LIABILITIES AND SHAREHOLDERS' EQUITY
Current
Finance lease liabilities	Current portion of long-term debt and finance lease obligations	$	4,586	$	4,616
Operating lease liabilities	Other accrued liabilities	9,507		9,877
Non-current
Finance lease liabilities	Long-term debt and finance lease obligations, net of current portion	37,379		36,919
Operating lease liabilities	Long-term operating lease liabilities	36,343		37,970
Total lease liabilities		$	87,815	$	89,382

8. Share-Based Compensation

The Company recognized $6.3 million and $5.3 million of compensation expense associated with share-based awards for the three months ended January 1, 2022 and January 2, 2021, respectively.

Performance stock units ("PSUs") are payable in shares of the Company's common stock. For PSUs issued in fiscal year 2020 and earlier, the PSUs vest based on the relative total shareholder return ("TSR") of the Company's common stock as compared to the companies in the Russell 3000 index, a market condition, and the Company's economic return performance during the performance period of three years, a performance condition. In the first quarter of fiscal 2021, the Company updated the market condition for PSUs based on TSR to the S&P 400 index for all future PSU grants, including those granted in fiscal year 2021. The Company uses the Monte Carlo valuation model to determine the fair value of PSUs at the date of grant for PSUs that vest based on the relative TSR of the Company's common stock. The Company uses its stock price on grant date as the fair value assigned to PSUs that vest based on the Company's economic return performance. The number of shares that may be issued pursuant to PSUs ranges from zero to 0.5 million and is dependent upon the Company's TSR and economic return performance over the applicable performance periods.

The Company recognizes share-based compensation expense over the share-based awards' vesting period.

9. Litigation

The Company is party to lawsuits in the ordinary course of business. Management does not believe that these proceedings, individually or in the aggregate, will have a material positive or adverse effect on the Company’s consolidated financial position, results of operations or cash flows.

Table of Contents

10. Reportable Segments

Reportable segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or group, in assessing performance and allocating resources. The Company uses an internal management reporting system, which provides important financial data to evaluate performance and allocate the Company’s resources on a regional basis. Net sales for the segments are attributed to the region in which the product is manufactured or the service is performed. The services provided, manufacturing processes used, class of customers serviced and order fulfillment processes used are similar and generally interchangeable across the segments. A segment’s performance is evaluated based upon its operating income (loss). A segment’s operating income (loss) includes its net sales less cost of sales and selling and administrative expenses, but excludes corporate and other expenses. Corporate and other expenses primarily represent corporate selling and administrative expenses, and restructuring costs and other charges, if any. These costs are not allocated to the segments, as management excludes such costs when assessing the performance of the segments. Inter-segment transactions are generally recorded at amounts that approximate arm’s length transactions. The accounting policies for the segments are the same as for the Company taken as a whole.

Information about the Company’s three reportable segments for the three months ended January 1, 2022 and January 2, 2021 is as follows (in thousands):

	Three Months Ended
	January 1, 2022		January 2, 2021
Net sales:
AMER	$	277,346	$	327,567
APAC	491,672		451,302
EMEA	72,863		78,723
Elimination of inter-segment sales	(24,425)		(27,237)
	$	817,456	$	830,355
Operating income (loss):
AMER	$	1,790	$	16,482
APAC	60,688		61,542
EMEA	956		(988)
Corporate and other costs	(32,961)		(30,170)
	$	30,473	$	46,866
Other income (expense):
Interest expense	$	(3,046)	$	(4,086)
Interest income	271		374
Miscellaneous, net	(923)		(1,518)
Income before income taxes	$	26,775	$	41,636	January 1,<br>2022	October 2,<br>2021
---	---	---	---	---
Total assets:
AMER	$	869,801	$	789,385
APAC	1,457,341		1,283,124
EMEA	276,273		275,122
Corporate and eliminations	106,231		114,262
	$	2,709,646	$	2,461,893

Table of Contents

11. Guarantees

The Company offers certain indemnifications under its customer manufacturing agreements. In the normal course of business, the Company may from time to time be obligated to indemnify its customers or its customers’ customers against damages or liabilities arising out of the Company’s negligence, misconduct, breach of contract, or infringement of third-party intellectual property rights. Certain agreements have extended broader indemnification, and while most agreements have contractual limits, some do not. However, the Company generally does not provide for such indemnities and seeks indemnification from its customers for damages or liabilities arising out of the Company’s adherence to customers’ specifications or designs or use of materials furnished, or directed to be used, by its customers. The Company does not believe its obligations under such indemnities are material.

In the normal course of business, the Company also provides its customers a limited warranty covering workmanship, and in some cases materials, on products manufactured by the Company. Such warranty generally provides that products will be free from defects in the Company’s workmanship and meet mutually agreed-upon specifications for periods generally ranging from 12 months to 24 months. The Company’s obligation is generally limited to correcting, at its expense, any defect by repairing or replacing such defective product. The Company’s warranty generally excludes defects resulting from faulty customer-supplied components, design defects or damage caused by any party or cause other than the Company.

The Company provides for an estimate of costs that may be incurred under its limited warranty at the time product revenue is recognized and establishes additional reserves for specifically identified product issues. These costs primarily include labor and materials, as necessary, associated with repair or replacement and are included in the Company's accompanying Condensed Consolidated Balance Sheets in "other accrued liabilities." The primary factors that affect the Company’s warranty liability include the value and the number of shipped units and historical and anticipated rates of warranty claims. As these factors are impacted by actual experience and future expectations, the Company assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary.

Below is a table summarizing the activity related to the Company’s limited warranty liability for the three months ended January 1, 2022 and January 2, 2021 (in thousands):

	Three Months Ended
	January 1, 2022		January 2, 2021
Reserve balance, beginning of period	$	6,645	$	6,386
Accruals for warranties issued during the period	1,258		465
Settlements (in cash or in kind) during the period	(741)		(1,066)
Reserve balance, end of period	$	7,162	$	5,785

12. Shareholders' Equity

On August 20, 2019, the Board of Directors approved a share repurchase program under which the Company is authorized to repurchase $50.0 million of its common stock (the "2019 Program"). During the three months ended January 2, 2021, the Company completed the 2019 Program by repurchasing 73,560 shares under this program for $5.3 million at an average price of $72.44 per share.

On August 13, 2020, the Board of Directors approved a share repurchase program under which the Company is authorized to repurchase up to $50.0 million of its common stock (the "2021 Program"). On November 18, 2020, the Board of Directors approved an additional $50.0 million in share repurchase authority under the existing 2021 Program such that there then existed a total of $100.0 million in share repurchase authority under the program. The 2021 Program commenced upon completion of the 2019 Program. During the three months ended January 2, 2021, the Company repurchased 233,511 shares under this program for $17.5 million at an average price of $74.70 per share.

On August 11, 2021, the Board of Directors approved a new share repurchase program that authorizes the Company to repurchase up to $50.0 million of its common stock (the "2022 Program"). The 2022 Program commenced upon completion of the 2021 Program. The 2022 Program has no expiration. During the three months ended January 1, 2022, the Company repurchased 110,440 shares under this program for $10.2 million at an average price of $91.74 per share. As of January 1, 2022, $36.7 million of authority remained under the 2022 Program.

All shares repurchased under the aforementioned programs were recorded as treasury stock.

Table of Contents

13. Trade Accounts Receivable Sale Programs

The Company has Master Accounts Receivable Purchase Agreements with MUFG Bank, New York Branch (formerly known as The Bank of Tokyo-Mitsubishi UFJ, Ltd.) (the "MUFG RPA"), HSBC Bank (China) Company Limited, Xiamen branch (the "HSBC RPA") and other unaffiliated financial institutions, under which the Company may elect to sell receivables; at a discount. All facilities are uncommitted facilities. The maximum facility amount under the MUFG RPA as of January 1, 2022 is $340.0 million. The maximum facility amount under the HSBC RPA as of January 1, 2022 is $60.0 million. The MUFG RPA will be automatically extended each year unless any party gives no less than 10 days prior notice that the agreement should not be extended. The terms of the HSBC RPA are generally consistent with the terms of the MUFG RPA previously discussed.

Transfers of receivables under the programs are accounted for as sales and, accordingly, receivables sold under the programs are excluded from accounts receivable on the Condensed Consolidated Balance Sheets and are reflected as cash provided by operating activities on the Condensed Consolidated Statements of Cash Flows. Proceeds from the transfer reflect the face value of the receivables less a discount. The sale discount is recorded within "Miscellaneous, net" in the Condensed Consolidated Statements of Comprehensive Income in the period of the sale. The Company continues servicing receivables sold and performing all accounts receivable administrative functions, in exchange receives a servicing fee, under both the MUFG RPA and HSBC RPA. Servicing fees related to trade accounts receivable programs recognized during the three months ended January 1, 2022 and January 2, 2021 were not material.

The Company sold $148.0 million and $198.4 million of trade accounts receivable under these programs, or their predecessors, during the three months ended January 1, 2022 and January 2, 2021, respectively, in exchange for cash proceeds of $147.5 million and $197.8 million, respectively. As of January 1, 2022 and October 2, 2021, $151.0 million and $176.0 million, respectively, of accounts receivables sold under trade accounts receivable programs and subject to servicing by the Company remained outstanding and had not yet been collected.

14. Revenue from Contracts with Customers

Significant Judgments

Revenue is recognized over time for arrangements with customers for which: (i) the Company's performance does not create an asset with an alternative use to the Company, and (ii) the Company has an enforceable right to payment, including reasonable profit margin, for performance completed to date. Revenue recognized over time is estimated based on costs incurred to date plus a reasonable profit margin. If either of the two conditions noted above are not met to recognize revenue over time, revenue is recognized following the transfer of control of such products to the customer, which typically occurs upon shipment or delivery depending on the terms of the underlying arrangement.

The Company recognizes revenue when a contract exists and when, or as, it satisfies a performance obligation by transferring control of a product or service to a customer. Contracts are accounted for when they have approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer.

The Company generally enters into a master services arrangement that establishes the framework under which business will be conducted. These arrangements represent the master terms and conditions of the Company's services that apply to individual orders, but they do not commit the customer to work with, or to continue to work with, the Company nor do they obligate the customer to any specific volume or pricing of purchases. Moreover, these terms can be amended in appropriate situations.

Customer purchase orders are received for specific quantities with predominantly fixed pricing and delivery requirements. Thus, for the majority of our contracts, there is no guarantee of any revenue to the Company until a customer submits a purchase order. As a result, the Company generally considers its arrangement with a customer to be the combination of the master services arrangement and the purchase order. Most of the Company's arrangements with customers create a single performance obligation as the promise to transfer the individual manufactured product or service is capable of being distinct.

Table of Contents

The Company’s performance obligations are satisfied over time as work progresses or at a point in time. A performance obligation is satisfied over time if the Company has an enforceable right to payment, including a reasonable profit margin. Determining if an enforceable right to payment includes a reasonable profit margin requires judgment and is assessed on a contract by contract basis.

Generally, there are no subjective customer acceptance requirements or further obligations related to goods or services provided; if such requirements or obligations exist, then a sale is recognized at the time when such requirements are completed and such obligations are fulfilled.

The Company does not allow for a general right of return. Net sales include amounts billed to customers for shipping and handling and out-of-pocket expenses. The corresponding shipping and handling costs and out-of-pocket expenses are included in cost of sales. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from net sales.

Contract Costs

For contracts requiring over time revenue recognition, the selection of the method to measure progress towards completion requires judgment and is based on the nature of the products or services to be provided. The Company uses a cost-based input measurement of progress because it best depicts the transfer of assets to the customer, which occurs as costs are incurred during the manufacturing process or as services are rendered. Under the cost-based measure of progress, the extent of progress towards completion is measured based on the costs incurred to date.

There were no other costs to obtain or fulfill customer contracts.

Disaggregated Revenue

The table below includes the Company’s revenue for the three months ended January 1, 2022 and January 2, 2021 and disaggregated by geographic reportable segment and market sector (in thousands):

	Three Months Ended
	January 1, 2022
	Reportable Segment:
	AMER		APAC		EMEA		Total
Market Sector:
Industrial	$	83,245	$	265,275	$	15,307	$	363,827
Healthcare/Life Sciences	135,962		169,237		39,266		344,465
Aerospace/Defense	55,750		35,743		17,671		109,164
External revenue	274,957		470,255		72,244		817,456
Inter-segment sales	2,389		21,417		619		24,425
Segment revenue	$	277,346	$	491,672	$	72,863	$	841,881
	Three Months Ended
---	---	---	---	---	---	---	---	---
	January 2, 2021
	Reportable Segment:
	AMER		APAC		EMEA		Total
Market Sector:
Industrial	$	122,026	$	238,248	$	17,768	$	378,042
Healthcare/Life Sciences	126,439		154,046		38,828		319,313
Aerospace/Defense	76,980		34,259		21,761		133,000
External revenue	325,445		426,553		78,357		830,355
Inter-segment sales	2,122		24,749		366		27,237
Segment revenue	$	327,567	$	451,302	$	78,723	$	857,592

Table of Contents

For each of the three months ended January 1, 2022 and January 2, 2021, approximately 87% and 91% of the Company's revenue, respectively, was recognized as the performance obligations for products and services were transferred over time.

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, contract assets and deferred revenue on the Company’s accompanying Condensed Consolidated Balance Sheets.

Contract Assets: For performance obligations satisfied at a point in time, billing occurs subsequent to revenue recognition, at which point the customer has been billed and the resulting asset is recorded within accounts receivable. For performance obligations satisfied over time as work progresses, the Company has an unconditional right to payment, which results in the recognition of contract assets. The following table summarizes the activity in the Company's contract assets during the three months ended January 1, 2022 and January 2, 2021 (in thousands):

	Three Months Ended
	January 1, 2022		January 2, 2021
Contract assets, beginning of period	$	115,283	$	113,946
Revenue recognized during the period	709,723		753,565
Amounts collected or invoiced during the period	(719,556)		(754,286)
Contract assets, end of period	$	105,450	$	113,225

Deferred Revenue: Deferred revenue is recorded when consideration is received from a customer prior to transferring goods or services to the customer under the terms of the contract, which is included in other accrued liabilities on the Condensed Consolidated Balance Sheets. As of January 1, 2022 and October 2, 2021 the balance of advance payments from customers that remained in other accrued liabilities was $133.2 million and $101.1 million, respectively. The advance payment is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect the company from the other party failing to adequately complete some or all of its obligations under the contract. Deferred revenue is recognized into revenue when all revenue recognition criteria are met. For performance obligations satisfied over time, recognition will occur as work progresses; otherwise deferred revenue will be recognized based upon shipping terms.

15. Restructuring and Impairment Charges

During the first quarter of fiscal 2022, the Company recorded $2.0 million of restructuring and impairment charges primarily due to employee severance costs associated with a facility transition in our APAC region. These charges are recorded within restructuring and impairment charges on the Condensed Consolidated Statements of Comprehensive Income. Restructuring liabilities are recorded within other accrued liabilities on the Condensed Consolidated Balance Sheets.

The Company recognized a tax benefit of $0.2 million related to restructuring and impairment charges in the three months ended January 1, 2022.

The Company's restructuring accrual activity for the three months ended January 1, 2022 is included in the table below (in thousands):

	Fixed Asset and Operating ROU Asset Impairment		Employee Termination and Severance Costs		Total
Accrual balance, as of October 2, 2021	$	—	$	71	$	71
Restructuring and impairment costs	255		1,766		2,021
Amounts utilized	(255)		(75)		(330)
Accrual balance, as of January 1, 2022	$	—	$	1,762	$	1,762

There was no material restructuring activity for the three months ended January 2, 2021.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

"SAFE HARBOR" CAUTIONARY STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995:

The statements contained in this Form 10-Q that are guidance or which are not historical facts (such as statements in the future tense and statements including believe, expect, intend, plan, anticipate, goal, target and similar terms and concepts), including all discussions of periods which are not yet completed, are forward-looking statements that involve risks and uncertainties. These risks and uncertainties include the evolving effect, which may intensify, of COVID-19 on our employees, customers, suppliers, and logistics providers, including the impact of governmental actions being taken to curtail the spread of the virus. Other risks and uncertainties include, but are not limited to: the effect of inflationary pressures on our costs of production, profitability, and on the economic outlook of our markets; the effects of shortages and delays in obtaining components as a result of economic cycles, natural disasters or otherwise; the risk of customer delays, changes, cancellations or forecast inaccuracies in both ongoing and new programs; the lack of visibility of future orders, particularly in view of changing economic conditions; the economic performance of the industries, sectors and customers we serve; the effects of tariffs, trade disputes, trade agreements and other trade protection measures; the effects of the volume of revenue from certain sectors or programs on our margins in particular periods; our ability to secure new customers, maintain our current customer base and deliver product on a timely basis; the risks of concentration of work for certain customers; the particular risks relative to new or recent customers, programs or services, which risks include customer and other delays, start-up costs, potential inability to execute, the establishment of appropriate terms of agreements, and the lack of a track record of order volume and timing; the effects of start-up costs of new programs and facilities or the costs associated with the closure or consolidation of facilities; possible unexpected costs and operating disruption in transitioning programs, including transitions between Company facilities; the risk that new program wins and/or customer demand may not result in the expected revenue or profitability; the fact that customer orders may not lead to long-term relationships; our ability to manage successfully and execute a complex business model characterized by high product mix and demanding quality, regulatory, and other requirements; the risks associated with excess and obsolete inventory, including the risk that inventory purchased on behalf of our customers may not be consumed or otherwise paid for by the customer, resulting in an inventory write-off; risks related to information technology systems and data security; the ability to realize anticipated savings from restructuring or similar actions, as well as the adequacy of related charges as compared to actual expenses; increasing regulatory and compliance requirements; the effects of U.S. Tax Reform, any tax law changes as a result of change in U.S. presidential administration, and of related foreign jurisdiction tax developments; current or potential future barriers to the repatriation of funds that are currently held outside of the United States as a result of actions taken by other countries or otherwise; the potential effects of jurisdictional results on our taxes, tax rates, and our ability to use deferred tax assets and net operating losses; the weakness of areas of the global economy; the effect of changes in the pricing and margins of products; raw materials and component cost fluctuations; the potential effect of fluctuations in the value of the currencies in which we transact business; the effects of changes in economic conditions, political conditions and tax matters in the United States and in the other countries in which we do business (including as a result of the United Kingdom’s exit from the European Union); the potential effect of other world or local events or other events outside our control (such as changes in energy prices, terrorism, global health epidemics and weather events); the impact of increased competition; an inability to successfully manage human capital; changes in financial accounting standards; and other risks detailed herein and in our other Securities and Exchange Commission filings, particularly in Risk Factors in our fiscal 2021 Form 10-K.

* * *

OVERVIEW

Plexus Corp. and its subsidiaries (together "Plexus," the "Company," or "we") participate in the Electronic Manufacturing Services ("EMS") industry. Since 1979, we have been partnering with companies to create the products that Build a Better World by providing Design and Development, Supply Chain Solutions, New Product Introduction, Manufacturing and Aftermarket Services. We are a global leader that specializes in serving customers in industries with highly complex products and demanding regulatory environments. Plexus delivers customer service excellence to leading companies by providing innovative, comprehensive solutions throughout a product’s lifecycle. We engineer innovative solutions for customers in growth markets and focus on partnering with leading global companies in the Industrial, Healthcare/Life Sciences and Aerospace/Defense market sectors. We deliver comprehensive end-to-end solutions in the Americas ("AMER"), Asia-Pacific ("APAC") and Europe, Middle East and Africa ("EMEA") regions.

Table of Contents

The following Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to provide an analysis of both short-term results and future prospects from management’s perspective, including an assessment of the financial condition and results of operations, events and uncertainties that are not indicative of future operations and any other financial or statistical data that we believe will enhance the understanding of our company’s financial condition, cash flows and other changes in financial condition and results of operations.

The following information should be read in conjunction with our condensed consolidated financial statements included herein and "Risk Factors" included in Part II, Item 1A included herein as well as Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended October 2, 2021, and our "Safe Harbor" Cautionary Statement included above .

COVID-19 Update

We continue to monitor the global outbreak and spread of COVID-19 and take steps to mitigate the potential risks to us posed by its spread and related circumstances and impacts.

The health and safety of our employees is a top priority for us. We have progressively implemented measures to safeguard our employees from the COVID-19 infection and exposure and have made significant efforts to mitigate the effects of regulatory authority restrictions on our operations through a combination of adjustments in our shift patterns, flexible work arrangements, productivity improvements, facility enhancements to support social distancing and optimizing employee capability to work from home, if needed. These efforts will continue as requirements change, new risks are identified and infections impact us.

We have experienced labor shortages due to COVID-19 quarantines or workforce curtailments, particularly in Malaysia during fiscal 2021, as the virus spread. The spread and resurgence of the COVID-19 virus from new variants in jurisdictions we operate may make our ability to mitigate the impacts of the pandemic on our productivity more challenging.

We remain in close contact with our suppliers to understand the impacts of COVID-19 on their businesses and operations. Our suppliers may face challenges in maintaining an adequate workforce or securing materials from their own suppliers as a result of COVID-19. We have experienced, and expect to continue to experience during the remainder of fiscal 2022, an inability to procure certain components and materials on a timely basis due to worsening supply chain shortages likely as a result of the COVID-19 pandemic. We continue to take steps to validate our suppliers’ ability to deliver to us on time. However, the extended lead times have required us to make additional investments in inventory to satisfy customer demand, which we expect to persist.

Worsening supply chain constraints have impacted our ability to meet customer demand, and as a result, negatively impacted revenue compared to expectations. The global supply chain constraints will limit our ability to capture the demand from our customers during fiscal 2022. We continue to maintain additional resources to help mitigate component constraint challenges and the operating inefficiencies COVID-19 has created, but note these inefficiencies place additional burden on operating results.

The global supply chain constraints have led to inflation in many of the components we acquire, as well as labor and operating costs. While we have been largely able to mitigate the impacts of inflation through our contractual rights with customers on pricing, the inability to offset these costs in future periods or the impacts of continued inflation on end markets and our customers may affect our operating results and inventory levels, which could increase as a result of higher component prices or the negative effects of inflation on customer demand.

We believe we are positioned with a strong balance sheet to face the potential future challenges presented by COVID-19. As of the first quarter of fiscal 2022, cash and cash equivalents and restricted cash were $218 million, while debt, finance lease obligations and other financing were $338 million. Borrowings under our Credit Facility as of January 1, 2022 were $140 million, leaving $210 million of our revolving commitment of $350 million available for use as of January 1, 2022 as well as the ability to expand our revolving commitment to $600 million upon mutual agreement with the bank. Refer to Note 3, "Debt, Finance Lease Obligations and Other Financing," in Notes to Condensed Consolidated Financial Statements and "Management’s Discussion and Analysis Liquidity and Capital Resources" in Part I, Item 2 for further information.

See "Risk Factors" contained in our Annual Report on Form 10-K for the fiscal year ended October 2, 2021, "Our financial condition and results of operations may be materially adversely affected by the ongoing coronavirus (COVID-19) outbreak" and "We experience component shortages, price fluctuations and supplier quality concerns."

Table of Contents

RESULTS OF OPERATIONS

Consolidated Performance Summary. The following table presents selected consolidated financial data (dollars in millions, except per share data):

	Three Months Ended
	January 1, 2022			January 2, 2021
Net sales	$	817.5		$	830.4
Cost of sales	747.5			751.1
Gross profit	70.0			79.3
Gross margin	8.6		%	9.5		%
Operating income	30.5			46.9
Operating margin	3.7		%	5.6		%
Other expense	3.7			5.2
Income tax expense	3.4			5.4
Net income	23.4			36.2
Diluted earnings per share	$	0.82		$	1.23
Return on invested capital*	10.0		%	16.3		%
Economic return*	0.7		%	8.2		%
*Non-GAAP metric; refer to "Return on Invested Capital ("ROIC") and economic return" below for more information and Exhibit 99.1 for a reconciliation.

Net sales. For the three months ended January 1, 2022, net sales decreased $12.9 million, or 1.6%, as compared to the three months ended January 2, 2021. The decrease in net sales was primarily driven by supply chain constraints, which has created limitations with meeting available customer demand and ramping new programs, partially offset by an increase in production ramps of new products with existing customers.

Net sales are analyzed by management by geographic segment, which reflects our reportable segments, and by market sector. Management measures operational performance and allocates resources on a geographic segment basis. Our global business development strategy is based on our targeted market sectors.

A discussion of net sales by reportable segment is presented below (in millions):

	Three Months Ended
	January 1, 2022		January 2, 2021
Net sales:
AMER	$	277.3	$	327.6
APAC	491.7		451.3
EMEA	72.9		78.7
Elimination of inter-segment sales	(24.4)		(27.2)
Total net sales	$	817.5	$	830.4

AMER. Net sales for the three months ended January 1, 2022 in the AMER segment decreased $50.3 million, or 15.4%, as compared to the three months ended January 2, 2021. The decrease in net sales was driven by overall net decreased customer end-market demand, inclusive of the impact of supply chain constraints that have created limitations with meeting available customer demand and ramping new programs. The decrease in net sales was also driven by a $6.8 million decrease due to a disengagement with a customer. These decreases were partially offset by a $12.4 million increase in production ramps of new products for existing customers.

Table of Contents

APAC. Net sales for the three months ended January 1, 2022 in the APAC segment increased $40.4 million, or 9.0%, as compared to the three months ended January 2, 2021. The increase in net sales was driven by overall net increased customer end-market demand, partially offset by the impact of supply chain constraints that have created limitations with meeting available customer demand and ramping new programs. The increase was also driven by a $20.2 million increase in production ramps of new products for existing customers. These increases were partially offset by a $7.2 million decrease for end-of-life products.

EMEA. Net sales for the three months ended January 1, 2022 in the EMEA segment decreased $5.8 million, or 7.4%, as compared to the three months ended January 2, 2021. The decrease in net sales was driven by overall net decreased customer end-market demand.

Our net sales by market sector were as follows (in millions):

	Three Months Ended
	January 1, 2022		January 2, 2021
Net sales:
Industrial	$	363.8	$	378.1
Healthcare/Life Sciences	344.5		319.3
Aerospace/Defense	109.2		133.0
Total net sales	$	817.5	$	830.4

Industrial. Net sales for the three months ended January 1, 2022 in the Industrial sector decreased $14.3 million, or 3.8%, as compared to the three months ended January 2, 2021. The decrease was driven by supply chain constraints that have created limitations with meeting available customer demand and ramping new programs, partially offset by overall net increased customer end-market demand, and a $6.8 million decrease due to a disengagement with a customer. The decrease was partially offset by an increase of $14.0 million due to production ramps of new products with existing customers.

Healthcare/Life Sciences. Net sales for the three months ended January 1, 2022 in the Healthcare/Life Sciences sector increased $25.2 million, or 7.9%, as compared to the three months ended January 2, 2021. The increase in net sales was driven by a $21.2 million increase in production ramps of new products with existing customers as well as overall net increased customer end-market demand, partially offset by the impact of supply chain constraints that have created limitations with meeting available customer demand and ramping new programs. The increase was partially offset by a $7.2 million decrease for end-of-life products, primarily as a result of decreased demand in critical care products likely due to COVID-19.

Aerospace/Defense. Net sales for the three months ended January 1, 2022 in the Aerospace/Defense sector decreased $23.8 million, or 17.9%, as compared to the three months ended January 2, 2021. The decrease was driven by net decreased customer end-market demand, primarily with commercial aerospace customers likely due to COVID-19, as well as the impact of supply chain constraints that have created limitations with meeting available customer demand and ramping new programs.

Cost of sales. Cost of sales for the three months ended January 1, 2022 decreased $3.6 million, or 0.5%, as compared to the three months ended January 2, 2021. Cost of sales is comprised primarily of material and component costs, labor costs and overhead. For the three months ended January 1, 2022 and January 2, 2021, approximately 89% of the total cost of sales was variable in nature and fluctuated with sales volumes. Approximately 87% of these costs were related to material and component costs.

As compared to the three months ended January 2, 2021, the decrease in cost of sales for the three months ended January 1, 2022 was primarily driven by the decrease in net sales. This was partially offset by an increase in fixed costs, reduced labor productivity and operational inefficiencies associated with supply chain constraints.

Gross profit. Gross profit for the three months ended January 1, 2022 decreased $9.3 million, or 11.7%, as compared to the three months ended January 2, 2021. Gross margin of 8.6% for the three months ended January 1, 2022 decreased 90 basis points compared to the three months ended January 2, 2021. The primary driver of the decrease in gross profit and gross margin as compared to fiscal 2021 was the decrease in net sales as well as the increase in fixed costs, reduced labor productivity and operational inefficiencies associated with supply chain constraints.

Table of Contents

Operating income. Operating income for the three months ended January 1, 2022 decreased $16.4 million, or 35.0%, as compared to the three months ended January 2, 2021 as a result of the decrease in gross profit, a $5.1 million increase in selling and administrative expenses ("S&A") and a $2.0 million increase in restructuring and impairment charges. The increase in S&A was primarily due to an increase in bad debt expense compared to recovery of a previously reserved customer receivable received during the three months ended January 2, 2021, as well as increased compensation costs. Operating margin of 3.7% for the three months ended January 1, 2022 decreased 190 basis points compared to the three months ended January 2, 2021, primarily due to the decrease in gross margin as a result of the factors previously discussed, the increase in S&A expenses and increased restructuring and impairment charges associated with employee severance costs for a facility transition in the APAC region.

A discussion of operating income by reportable segment is presented below (in millions):

	Three Months Ended
	January 1, 2022		January 2, 2021
Operating income (loss):
AMER	$	1.8	$	16.5
APAC	60.7		61.5
EMEA	1.0		(1.0)
Corporate and other costs	(33.0)		(30.1)
Total operating income	$	30.5	$	46.9

AMER. Operating income decreased $14.7 million for the three months ended January 1, 2022 as compared to the three months ended January 2, 2021, primarily as a result of a decrease in net sales, reductions in labor productivity attributable to supply chain constraints, an increase in bad debt expense compared to recovery of a previously reserved customer receivable for the three months ended January 2, 2021, and increased fixed costs. This was partially offset by a positive shift in customer mix.

APAC. Operating income decreased $0.8 million for the three months ended January 1, 2022 as compared to the three months ended January 2, 2021, primarily as a result of reductions in labor productivity attributable to supply chain constraints, an increase in fixed costs and a negative shift in customer mix. This was partially offset by an increase in net sales.

EMEA. Operating income increased $2.0 million for the three months ended January 1, 2022 as compared to the three months ended January 2, 2021 primarily as a result of a positive shift in customer mix. This was partially offset by a decrease in net sales.

Other expense. Other expense for the three months ended January 1, 2022 decreased $1.5 million as compared to the three months ended January 2, 2021. The decrease in other expense was primarily due to the decrease in interest expense of $1.0 million and a decrease of $0.5 million in foreign exchange losses.

Income taxes. Income tax expense for the three months ended January 1, 2022 was $3.4 million compared to $5.4 million for the three months ended January 2, 2021. The decrease is primarily due to a decrease in income before taxes as well as additional discrete tax benefits of $0.6 million, partially offset by a change in the geographic distribution of worldwide earnings.

Our annual effective tax rate varies from the U.S. statutory rate of 21.0% primarily due to the geographic distribution of worldwide earnings as well as a tax holiday granted to a subsidiary located in the APAC segment where we derive a significant portion of our earnings. Our effective tax rate may also be impacted by disputes with taxing authorities, tax planning activities, adjustments to uncertain tax positions and changes in valuation allowances.

The annual effective tax rate for fiscal 2022 is expected to be approximately 13.0% to 15.0% assuming no changes to tax laws.

Net Income. Net income for the three months ended January 1, 2022 decreased $12.8 million, or 35.4%, from the three months ended January 2, 2021 to $23.4 million. Net income decreased primarily as a result of the decrease in operating income, partially offset by the decrease in other expense and tax expense as previously discussed.

Diluted earnings per share. Diluted earnings per share decreased to $0.82 for the three months ended January 1, 2022 from $1.23 for the three months ended January 2, 2021 primarily as a result of decreased net income due to the factors discussed above, partially offset by a reduction in diluted shares outstanding due to repurchase activity under our share repurchase plans.

Table of Contents

Return on Invested Capital ("ROIC") and economic return. We use a financial model that is aligned with our business strategy and includes a ROIC goal of 15%.

Non-GAAP financial measures, including ROIC and economic return, are used for internal management goals and decision making because such measures provide management and investors additional insight into financial performance. In particular, we provide ROIC and economic return because we believe they offer insight into the metrics that are driving management decisions because we view ROIC and economic return as important measures in evaluating the efficiency and effectiveness of our long-term capital requirements. We also use ROIC as a performance criteria in determining certain elements of compensation and certain compensation incentives are based on economic return performance.

We define ROIC as tax-effected operating income before restructuring and other special items divided by average invested capital over a rolling two-quarter period for the first quarter. Invested capital is defined as equity plus debt and operating lease liabilities, less cash and cash equivalents. Other companies may not define or calculate ROIC in the same way. ROIC and other non-GAAP financial measures should be considered in addition to, not as a substitute for, measures of our financial performance prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). We define economic return as ROIC less our weighted average cost of capital ("WACC").

We review our internal calculation of WACC annually. Our WACC is 9.3% for fiscal 2022 as compared to 8.1% for fiscal 2021. By exercising discipline to generate ROIC in excess of our WACC, our goal is to create value for our shareholders. For the three months ended January 1, 2022, ROIC of 10.0% reflects an economic return of 0.7%, based on our weighted average cost of capital of 9.3%. For the three months ended January 2, 2021, ROIC of 16.3% reflects an economic return of 8.2%, based on our weighted average cost of capital of 8.1% for that fiscal year.

For a reconciliation of ROIC, economic return and adjusted operating income (tax effected) to our financial statements that were prepared using GAAP, see Exhibit 99.1 to this quarterly report on Form 10-Q, which exhibit is incorporated herein by reference.

Refer to the table below, which includes the calculation of ROIC and economic return for the indicated fiscal years (dollars in millions):

	Three Months Ended
	January 1, 2022			January 2, 2021
Adjusted operating income (tax effected)	$	113.1		$	163.1
Average invested capital	1,135.3			1,002.1
After-tax ROIC	10.0		%	16.3		%
WACC	9.3		%	8.1		%
Economic return	0.7		%	8.2		%

LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents and restricted cash were $218.4 million as of January 1, 2022, as compared to $270.5 million as of October 2, 2021.

As of January 1, 2022, 90.4% of our cash and cash equivalents balance was held outside of the U.S. by our foreign subsidiaries. Currently, we believe that our cash balance, together with cash available under our Credit Facility, will be sufficient to meet our liquidity needs and potential share repurchases, if any, for the next twelve months and for the foreseeable future.

Table of Contents

Our future cash flows from operating activities will be reduced by $53.6 million due to cash payments for U.S. federal taxes on the deemed repatriation of undistributed foreign earnings that are payable over an eight year period that began in fiscal 2019 with the first payment. The table below provides the expected timing of these future cash outflows, in accordance with the following installment schedule for the remaining five years (in millions):

Remaining 2022	$	5.6
2023	5.6
2024	10.6
2025	14.2
2026	17.6
Total	$	53.6

Cash Flows. The following table provides a summary of cash flows (in millions):

	Three Months Ended
	January 1, 2022		January 2, 2021
Cash(used in) provided by operating activities	$	(89.0)	$	6.7
Cash used in investing activities	(33.4)		(15.8)
Cash provided by (used in) financing activities	70.0		(24.8)

Operating Activities. Cash flows used by operating activities were $89.0 million for the three months ended January 1, 2022, as compared to cash flows provided by operating activities of $6.7 million for the three months ended January 2, 2021. The decrease was primarily due to cash flow (reductions) improvements of:

•$(12.8) million decrease in net income.

•$(218.1) million in inventory cash flows driven by increased inventory levels to support the ramp of customer programs. In addition, there are longer lead times for certain components as a result of supply chain constraints heightened by the COVID-19 outbreak increasing our inventory level as we maintain components for remainder of the product.

•$(73.7) million in accounts receivable cash flows driven by timing of customer shipments, mix of customer payment terms and payments as well as decreased factoring activity.

•$99.7 million in accounts payables cash flows driven by increased purchasing activity to support the ramp of customer programs.

•$65.8 million in customer deposit cash flows driven by significant deposits received from four customers in the current year to cover certain inventory balances associated with longer lead times as a result of supply chain constraints heightened by the COVID-19 outbreak.

•$35.0 million in other current and non-current liabilities cash flows driven by an increase in advance payments from customers.

•$9.0 million in contract assets cash flows driven by decreased demand from customers who recognize revenue over time in the current year compared to consistent demand in the prior year.

The following table provides a summary of cash cycle days for the periods indicated (in days):

	Three Months Ended
	January 1,<br>2022	January 2, 2021
Days in accounts receivable	66	53
Days in contract assets	12	12
Days in inventory	145	93
Days in accounts payable	(87)	(59)
Days in cash deposits	(33)	(19)
Annualized cash cycle	103	80

Table of Contents

We calculate days in accounts receivable and contract assets as each balance sheet item for the respective quarter divided by annualized sales for the respective quarter by day. We calculate days in inventory, accounts payable and cash deposits as each balance sheet line item for the respective quarter divided by annualized cost of sales for the respective quarter by day. We calculate annualized cash cycle as the sum of days in accounts receivable, days in contract assets and days in inventory, less days in accounts payable and days in cash deposits.

As of January 1, 2022, annualized cash cycle days increased twenty-three days compared to January 2, 2021 due to the following:

Days in accounts receivable for the three months ended January 1, 2022 increased thirteen days compared to the three months ended January 2, 2021. The increase is primarily attributable to the timing of customer shipments and payments, mix of customer payment terms and a decrease in factored receivables.

Days in contract assets for the three months ended January 1, 2022 remained flat compared to the three months ended January 2, 2021.

Days in inventory for the three months ended January 1, 2022 increased fifty-two days compared to the three months ended January 2, 2021. The increase is primarily attributable to increased inventory levels to support the ramp of customer programs, as well as the decrease in net sales. In addition, there are longer lead times for certain components as a result of supply chain constraints heightened by the COVID-19 outbreak increasing our inventory level as we maintain components for remainder of the product.

Days in accounts payable for the three months ended January 1, 2022 increased twenty-eight days compared to the three months ended January 2, 2021. The increase is primarily attributable to increased purchasing activity and supply chain constraints to obtain certain components heightened by the COVID-19 outbreak, as well as the decrease in net sales.

Days in cash deposits for the three months ended January 1, 2022 increased fourteen days compared to the three months ended January 2, 2021. The increase was primarily attributable to significant deposits received from four customers to cover certain inventory balances.

Free Cash Flow. We define free cash flow ("FCF"), a non-GAAP financial measure, as cash flow (used in) provided by operations less capital expenditures. FCF was $(122.2) million for the three months ended January 1, 2022 compared to $(9.2) million for the three months ended January 2, 2021, a decrease of $113.0 million.

Non-GAAP financial measures, including FCF, are used for internal management assessments because such measures provide additional insight to investors into ongoing financial performance. In particular, we provide FCF because we believe it offers insight into the metrics that are driving management decisions. We view FCF as an important financial metric as it demonstrates our ability to generate cash and can allow us to pursue opportunities that enhance shareholder value. FCF is a non-GAAP financial measure that should be considered in addition to, not as a substitute for, measures of our financial performance prepared in accordance with GAAP.

A reconciliation of FCF to our financial statements that were prepared using GAAP follows (in millions):

	Three Months Ended
	January 1,<br>2022		January 2, 2021
Cash flows (used in) provided by operating activities	$	(89.0)	$	6.7
Payments for property, plant and equipment	(33.2)		(15.9)
Free cash flow	$	(122.2)	$	(9.2)

Investing Activities. Cash flows used in investing activities were $33.4 million for the three months ended January 1, 2022 compared to $15.8 million for the three months ended January 2, 2021. The increase in cash used in investing activities was due to a $17.4 million increase in capital expenditures, primarily due to our manufacturing footprint expansion in Bangkok, Thailand.

We estimate funded capital expenditures for fiscal 2022 will be approximately $100.0 million to $120.0 million, of which $33.2 million was utilized through the first three months of fiscal 2022. The remaining fiscal 2022 capital expenditures are anticipated to be used primarily for our manufacturing footprint expansion in Bangkok, Thailand, and to support new program ramps and replace older equipment.

Table of Contents

Financing Activities. Cash flows provided by financing activities were $70.0 million for the three months ended January 1, 2022 compared to cash flows used in financing activities of $24.8 million for the three months ended January 2, 2021. The increase was primarily attributable to an increase of $83.6 million in net borrowings on the Credit Facility and a decrease of $12.6 million in cash used to repurchase our common stock.

On August 20, 2019, the Board of Directors approved a share repurchase program under which we were authorized to repurchase $50.0 million of our common stock (the "2019 Program"). During the three months ended January 2, 2021, we completed the 2019 Program by repurchasing 73,560 shares under this program for $5.3 million at an average price of $72.44 per share.

On August 13, 2020, the Board of Directors approved a share repurchase program under which we were authorized to repurchase up to $50.0 million of our common stock (the "2021 Program"). On November 18, 2020, the Board of Directors approved an additional $50.0 million in share repurchase authority under the existing 2021 Program such that there then existed a total of $100.0 million in share repurchase authority under the program. The 2021 program commenced upon completion of the 2019 Program. During the three months ended January 2, 2021, we repurchased 233,511 shares under this program for $17.5 million at an average price of $74.70 per share.

On August 11, 2021, the Board of Directors approved a new share repurchase program under which we were authorized to repurchase up to $50.0 million of its common stock (the "2022 Program"). The 2022 Program commenced upon completion of the 2021 Program. The 2022 Program has no expiration. During the three months ended January 1, 2022, we repurchased 110,440 shares under this program for $10.2 million at an average price of $91.74 per share. As of January 1, 2022, $36.7 million of authority remained under the 2022 Program.

All shares repurchased under the aforementioned programs were recorded as treasury stock.

On June 15, 2018, we entered into a Note Purchase Agreement (the “2018 NPA”) pursuant to which we issued an aggregate of $150.0 million in principal amount of unsecured senior notes, consisting of $100.0 million in principal amount 4.05% Series A Senior Notes, due on June 15, 2025, and $50.0 million in principal amount of 4.22% Series B Senior Notes, due on June 15, 2028 (collectively, the “2018 Notes”), in a private placement. The 2018 NPA includes customary operational and financial covenants with which we are required to comply, including, among others, maintenance of certain financial ratios such as a total leverage ratio and a minimum interest coverage ratio. The 2018 Notes may be prepaid in whole or in part at any time, subject to payment of a make-whole amount; interest on the 2018 Notes is payable semiannually. As of January 1, 2022, we were in compliance with the covenants under the 2018 NPA.

On May 15, 2019, we refinanced our then-existing senior unsecured revolving credit facility by entering into a new five-year senior unsecured revolving credit facility (referred to as the "Credit Facility"), which expanded the maximum commitment from $300.0 million to $350.0 million and extended the maturity from July 5, 2021 to May 15, 2024. The maximum commitment under the Credit Facility may be further increased to $600.0 million, generally by mutual agreement of the lenders and us, subject to certain customary conditions. During fiscal 2022, the highest daily borrowing was $186.0 million; the average daily borrowings were $117.9 million. We borrowed $181.0 million and repaid $96.0 million of revolving borrowings ("revolving commitment") under the Credit Facility during fiscal 2022. As of January 1, 2022, we were in compliance with all financial covenants relating to the Credit Facility, which are generally consistent with those in the 2018 NPA discussed above. We are required to pay a commitment fee on the daily unused revolving commitment based on our leverage ratio; the fee was 0.125% as of January 1, 2022.

To further ensure our ability to meet our working capital and fixed capital requirements, on April 29, 2020, we entered into Amendment No. 1 to the Credit Facility (the "Amendment") in response to the COVID-19 outbreak, which amended the Credit Facility, dated as of May 15, 2019. The Amendment modified certain provisions of the Credit Facility to, among other things, provide Term Loans for $138.0 million. Term Loans borrowed under the new facility were funded in a single draw on May 4, 2020 and were scheduled to mature on April 28, 2021. On January 29, 2021, we terminated the Term Loans through repayment of the $138.0 million outstanding using borrowings from the revolving commitment under the Credit Facility. Outstanding Term Loans bore interest, at our option, at a eurocurrency rate (subject to a floor of 1.0%) plus a margin of 1.75% per annum or at a base rate (subject to a floor of 2.0%) plus a margin of 0.75% per annum.

The Credit Facility and the 2018 NPA allow for the future payment of cash dividends or the repurchase of shares provided that no event of default (including any failure to comply with a financial covenant) exists at the time of, or would be caused by, the dividend payment or the share repurchases. We have not paid cash dividends in the past. However, we evaluate from time to time potential uses of excess cash, which in the future may include share repurchases above those already authorized, a special dividend or recurring dividends.

Table of Contents

We have Master Accounts Receivable Purchase Agreements with MUFG Bank, New York Branch (formerly known as The Bank of Tokyo-Mitsubishi UFJ, Ltd.) (the "MUFG RPA"), HSBC Bank (China) Company Limited, Xiamen branch (the "HSBC RPA") and other unaffiliated financial institutions, under which we may elect to sell receivables, at a discount, on an ongoing basis. These facilities are uncommitted facilities. The maximum facility amount under the MUFG RPA as of January 1, 2022 is $340.0 million. The maximum facility amount under the HSBC RPA as of January 1, 2022 is $60.0 million. The MUFG RPA will be automatically extended each year unless any party gives no less than 10 days prior notice that the agreement should not be extended. The terms of the HSBC RPA are generally consistent with the terms of the MUFG RPA previously discussed.

We sold $148.0 million and $198.4 million of trade accounts receivable under these programs during the three months ended January 1, 2022 and January 2, 2021, respectively, in exchange for cash proceeds of $147.5 million and $197.8 million, respectively. As of January 1, 2022 and October 2, 2021, $151.0 million and $176.0 million, respectively, of accounts receivables sold under trade accounts receivable programs and subject to servicing by us remained outstanding and had not yet been collected.

In all cases, the sale discount was recorded within "Miscellaneous, net" in the Condensed Consolidated Statements of Comprehensive Income in the period of the sale. For further information regarding the receivable sale programs, see Note 13, "Trade Accounts Receivable Sale Programs," in Notes to Condensed Consolidated Financial Statements.

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents, potential borrowings under the Credit Facility and our leasing capabilities should be sufficient to meet our working capital and fixed capital requirements, as well as execution upon our share repurchase authorizations as management deems appropriate, for the next twelve months. We believe our balance sheet is positioned to support the potential future challenges presented by COVID-19, including increased working capital requirements associated with longer lead time for components, increased component and labor costs, and operating inefficiencies due to supply chain constraints or workplace safety restrictions. As of the end of the first quarter of fiscal 2022, cash and cash equivalents and restricted cash were $218 million, while debt, finance lease obligations and other financing were $338 million. We have significant funding availability through our Credit Facility, should future needs arise. If our future financing needs increase, then we may need to arrange additional debt or equity financing. Accordingly, we evaluate and consider from time to time various financing alternatives to supplement our financial resources. However, we cannot be assured that we will be able to make any such arrangements on acceptable terms.

Table of Contents

DISCLOSURE ABOUT CRITICAL ACCOUNTING POLICIES

Our critical accounting policies are disclosed in our 2021 Annual Report on Form 10-K. During the first quarter of fiscal 2022, there were no material changes.

NEW ACCOUNTING PRONOUNCEMENTS

See Note 1, "Basis of Presentation," in Notes to Condensed Consolidated Financial Statements regarding recent accounting pronouncements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to market risk from changes in foreign exchange and interest rates. We selectively use financial instruments to reduce such risks. We do not use derivative financial instruments for speculative purposes.

Foreign Currency Risk

Our international operations create potential foreign exchange risk. Our policy is to selectively hedge our foreign currency denominated transactions in a manner that partially offsets the effects of changes in foreign currency exchange rates. We typically use foreign currency contracts to hedge only those currency exposures associated with certain assets and liabilities denominated in non-functional currencies. Corresponding gains and losses on the underlying transaction generally offset the gains and losses on these foreign currency hedges. We cannot predict changes in currency rates, nor the degree to which we will be able to manage the impacts of currency exchange rate changes, including the impacts on currency exchange rates related to the COVID-19 outbreak. Such changes could have a material effect on our business, results of operations and financial condition.

Our percentages of transactions denominated in currencies other than the U.S. dollar for the indicated periods were as follows:

	Three Months Ended
	January 1, 2022	January 2, 2021
Net Sales	10%	10%
Total Costs	18%	16%

We have evaluated the potential foreign currency exchange rate risk on transactions denominated in currencies other than the U.S. dollar for the periods presented above. Based on our overall currency exposure, as of January 1, 2022, a 10.0% change in the value of the U.S. dollar relative to our other transactional currencies would not have a material effect on our financial position, results of operations, or cash flows.

Interest Rate Risk

We have financial instruments, including cash equivalents and debt, which are sensitive to changes in interest rates. The primary objective of our investment activities is to preserve principal, while maximizing yields without significantly increasing market risk. To achieve this, we limit the amount of principal exposure to any one issuer. We cannot predict changes in interest rates, including the impacts on interest rates related to the COVID-19 outbreak.

As of January 1, 2022, our only material interest rate risk is associated with our Credit Facility. Revolving commitments under the Credit Facility bear interest, at our option, at a eurocurrency or base rate plus, in each case, an applicable interest rate margin based on our then-current leverage ratio (as defined in the Credit Facility). As of January 1, 2022, the borrowing rate under the Credit Facility was LIBOR plus 1.10%. Borrowings under the 2018 NPA are based on a fixed interest rate, thus mitigating much of our interest rate risk. Based on our overall interest rate exposure, as of January 1, 2022, a 10.0% change in interest rates would not have a material effect on our financial position, results of operations, or cash flows.

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures designed to ensure that the information the Company must disclose in its filings with the Securities and Exchange Commission ("SEC") is recorded, processed, summarized and reported on a timely basis. The Company’s Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") have reviewed and evaluated, with the participation of the Company’s management, the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") as of the end of the period covered by this report (the "Evaluation Date"). Based on such evaluation, the CEO and CFO have concluded that, as of the Evaluation Date, the Company’s disclosure controls and procedures are effective, at the reasonable assurance level, (a) in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act, and (b) in assuring that information is accumulated and communicated to the Company’s management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

During the first quarter of fiscal 2022 there have been no changes in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1A. Risk Factors

In addition to the risks and uncertainties discussed herein, particularly those discussed in the “Safe Harbor” Cautionary Statement and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in Part I, Item 2, see the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended October 2, 2021 that have had no material changes.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table provides the specified information about the repurchases of shares by us during the three months ended January 1, 2022:

Period	Total number of shares purchased	Average price paid per share		Total number of shares purchased as part of publicly announced plans or programs	Maximum approximate dollar value of shares that may yet be purchased under the plans or programs (1)
October 3, 2021 - <br>October 30, 2021	31,216	$	93.41	31,216	$	43,960,950
October 31, 2021 -<br>November 27, 2021	37,160	91.40		37,160	40,564,577
November 28, 2021 -<br>January 1, 2022	42,064	90.79		42,064	$	36,745,401
	110,440	$	91.74	110,440

(1) On August 11, 2021, the Board of Directors approved a new share repurchase program that authorizes the Company to repurchase up to $50.0 million of its common stock (the "2022 Program"). The 2022 Program commenced upon completion of the 2021 Program during the fourth quarter of fiscal 2021. The 2022 Program has no expiration. The table above reflects the maximum dollar amount remaining available for purchase under the 2022 Program as of January 1, 2022.

Table of Contents

ITEM 6. EXHIBITS

The list of exhibits is included below:

Exhibit <br>No.	Exhibit
10.1	Suspension of Rights under Credit Agreement relating to LIBOR.
10.2	Summary of Directors' Compensation effective January 1, 2022 .*
31.1	Certification of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
32.1	Certification of the CEO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of the CFO pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
99.1	Reconciliation of ROIC to GAAP and Economic Return Financial Statements.
101	The following materials from Plexus Corp.’s Quarterly Report on Form 10-Q for the fiscal quarter ended January 1, 2022, formatted in Inline Extensible Business Reporting Language ("XBRL"): (i) the Condensed Consolidated Statements of Comprehensive Income, (ii) the Condensed Consolidated Balance Sheets, (iii) the Condensed Consolidated Statements of Shareholders’ Equity, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.
101.INS	Inline XBRL Instance Document (the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document).
101.SCH	Inline XBRL Taxonomy Extension Schema Document.
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.
104	The cover page from the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended January 1, 2022, formatted in Inline XBRL and contained in Exhibit 101.

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Plexus Corp.
		Registrant
Date:	February 4, 2022	/s/ Todd P. Kelsey
		Todd P. Kelsey
		Chief Executive Officer
Date:	February 4, 2022	/s/ Patrick J. Jermain
		Patrick J. Jermain
		Executive Vice President and Chief Financial Officer

Document

SUSPENSION OF RIGHTS AGREEMENT

To: JPMorgan Chase Bank, N.A., as Administrative Agent

From: Plexus Corp.

Date: December 1, 2021

Ladies & Gentlemen

Reference is made to that certain Credit Agreement, dated as of May 15, 2019, among Plexus Corp. (the “Company”), the Subsidiary Borrowers from time to time party thereto (together with the Company, the “Borrowers”), the Lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Administrative Agent”) (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”).

1We are writing to you in your capacity as Administrative Agent under the Credit

Agreement. Unless otherwise defined in this letter, terms defined in the Credit Agreement have the same meaning when used in this letter. The term “Non-USD Currency” in this letter shall mean collectively or individually:

☒ Pounds Sterling

☒ EUR

☐ CHF

☐ JPY

2The Borrowers each acknowledge that from December 31, 2021, panel submissions for all Non-USD Currency LIBOR tenors and 1-week and 2-month Dollar denominated LIBOR tenors shall cease, following which representative LIBOR rates for such currencies and tenors shall cease to be available (the “2021 LIBOR Cessation”). As used herein, (a) “LIBOR” means, for any currency, the London interbank offered rate for such currency, and (b) “Cessation Date” means December 31, 2021; provided that (i) if the Financial Conduct Authority issues a public statement (each, an “Extension Statement”) extending the deadline date for the cessation of publishing Pounds Sterling LIBOR and/or EUR LIBOR for certain tenors that is representative of underlying market conditions and is recommended for continued use in business loans to a date that is after December 31, 2021, then “Cessation Date” with respect to Pounds Sterling denominated Loans and Advances and/or EUR denominated Loans and Advances, as applicable, with such tenors shall mean such later date of cessation specified in the applicable Extension Statement or (ii) if the Financial Conduct Authority issues an Extension Statement extending the deadline date for the cessation of publishing a one-week or two-month Dollar LIBOR that is representative of underlying market conditions and is recommended for continued use in business loans to a date that is after December 31, 2021, then “Cessation Date” with respect to such one-week and/or two-month Dollar denominated Loans and Advances, as applicable, shall mean such later date of cessation specified in the applicable Extension Statement.

3For good and valuable consideration, including delaying the incurrence of costs required to update the terms of the Credit Agreement in connection with the 2021 LIBOR Cessation, and in lieu of amending or waiving any term of the Credit Agreement, each of the Borrowers agrees with effect from December 1, 2021 to suspend its following rights under the Credit Agreement:

(a)Each Borrower agrees that, notwithstanding anything to the contrary in the Loan Documents, (i) from and after the Cessation Date, (A) the Non-USD Currency shall no longer be an Eligible Currency under the Credit Agreement, (B) the Non-USD Currency shall not be available as an Agreed Currency for Facility LCs issued under the Credit Agreement and (C) the Non-USD Currency shall not be available as an Agreed Currency for Loans under the Credit Agreement and no Lender shall be obligated to participate in any Advance under the Credit Agreement in the Non-USD Currency, and (ii) any and all outstanding Non-USD Currency Loans and Advances shall be repaid or prepaid by the Borrowers on or before the Cessation Date;

(b)Each Borrower agrees that, notwithstanding anything to the contrary in the Loan Documents, from and after the Cessation Date, it shall no longer be permitted to select an Interest Period of one week or two months for any Advance denominated in Dollars, in each case, without consent of the Required Lenders under the Credit Agreement (the preceding clause (a) and this clause (b) together, the “Suspension of Rights”); and

(c)Each Borrower agrees that, if any Borrower gives a notice or instruction under the Credit Agreement (i) after the Cessation Date that selects a Non-USD Currency as the currency of a Facility LC, such notice or instruction shall be deemed to be amended to select Dollars as the currency of that Facility LC or (ii) after the Cessation Date that selects (x) a Non-USD Currency as the currency of a Loan, such notice or instruction shall be deemed to be amended to select Dollars as the currency of that Loan, or (y) an Interest Period under the Credit Agreement that uses a 2-month LIBOR for Dollars to calculate interest (unless with the consent of the Required Lenders as contemplated by clause (b) above), such notice or instruction shall be deemed to be amended to select an Interest Period of 1 month and, in each case, agrees that only such amended notice or instruction will have effect under the Credit Agreement.

4The Suspension of Rights shall cease to have effect (and all rights of the Borrowers under the Credit Agreement in respect of the terms set out in paragraph 3 above in effect immediately prior to the Suspension of Rights shall be in full force and effect) following notice from the Company to the Administrative Agent that the Suspension of Rights is terminated, provided that, such notice shall only be effective if, prior to or contemporaneously with the date of such notice, amendments to the Credit Agreement to take account of the 2021 LIBOR Cessation and to replace LIBOR with an alternative benchmark with respect to Non-USD Currency Loans and Facility LCs have become effective pursuant to and in accordance with the terms of the Credit Agreement.

5Each of the Borrowers agrees to indemnify and hold harmless the Administrative Agent and each other indemnified person for any damage, loss, cost, liability, claim or reasonable expense whatsoever incurred (A) in connection with a breach, or reasonably in anticipation of a potential breach, of any Borrower’s agreements in paragraphs 3(a) and 3(b) above or (B) giving effect to the instruction of any Borrower in paragraph 3(c) above; provided that such indemnity shall not, as to the Administrative Agent and each other indemnified person, be available to the extent that such damage, loss, cost, liability, claim or reasonable expense (i) is determined in a final non-appealable judgment by a court of competent jurisdiction to have resulted from (A) the Administrative Agent’s or such indemnified person’s gross negligence or willful misconduct or (B) a material breach by the Administrative Agent or such indemnified person of its express obligations under the applicable Loan Document, or (ii) results from claims of any indemnified person solely against one or more other indemnified persons (other than any claims against an indemnified person in its capacity as the Administrative Agent, a Syndication Agent, a Co-Documentation Agent, an Arranger, an LC Issuer or the Swing Line Lender) that have not resulted from the action, inaction, participation or contribution of any Borrower or their respective Subsidiaries or any of their respective officers, directors, stockholders, partners, members, employees, agents, representatives or advisors.

6This letter is hereby designated as a Loan Document and we acknowledge that this letter will be posted to the Syndtrak site established for Lenders for the Credit Agreement. We acknowledge and agree that each Lender under the Credit Agreement may rely on and shall be a third party beneficiary of this letter.

7Please sign and return to us the enclosed copy of this notice by way of your acknowledgement to the contents set out in this letter. This letter may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument. The words “execution,” “signed,” “signature,” and words of like import in any Loan Document shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, or any other state laws based on the Uniform Electronic Transactions Act

8This letter has been duly executed and delivered by the Company, on behalf itself and each other Borrower, and constitutes a legal, valid and binding obligation of each of the Borrowers, enforceable in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law.

9The provisions of Section 15.1 (Governing Law), Section 15.2 (Jurisdiction) and Section

15.3 (Waiver of Jury Trial) shall apply, mutatis mutandis, to this letter.

[Signature pages follow]

Very truly yours,

PLEXUS CORP.

As the Company:

By: /s/ Patrick J. Jermain

Name: Patrick J. Jermain

Title: Executive Vice President & Chief Financial Officer

Agreed and accepted by:

JPMorgan Chase Bank, N.A.

as Administrative Agent

By: /s/ David Tepper

Name: David Tepper

Title Vice President

Document

PLEXUS CORP.

ANNUAL BOARD OF DIRECTORS AND COMMITTEE COMPENSATION

Effective January 1, 2022

______________________________________________________________________________

BOARD MEMBERS AND BOARD LEADERSHIP

______________________________________________________________________________

Chairman Retainer	$	250,000.00	USD
Board Member Retainer (all directors)	$	90,000.00	USD
Lead Director Retainer	$	120,000.00	USD

______________________________________________________________________________

COMMITTEE MEMBERS

______________________________________________________________________________

AUDIT COMMITTEE

COMPENSATION & LEADERSHIP DEVELOPMENT COMMITTEE (“COMPENSATION COMMITTEE”)

NOMINATING & CORPORATE GOVERNANCE COMMITTEE (“NOMINATING COMMITTEE”)

______________________________________________________________________________

Compensation Committee Chairman Retainer	$	10,000.00	USD
Nominating Committee Chairman Retainer	$	10,000.00	USD
Audit Committee Chairman Retainer	$	10,000.00	USD

______________________________________________________________________________

DIRECTOR EQUITY COMPENSATION

______________________________________________________________________________

Restricted Stock Units (“RSUs”) with a value of $175,000 (# of RSUs determined by dividing $175,000 by the 90-day average close price ending on 01 DEC each year). RSUs are subject to a one year cliff vesting from the date of grant.

______________________________________________________________________________

EDUCATIONAL EXPENSE REIMBURSEMENT

______________________________________________________________________________

Plexus will reimburse each director for the out-of-pocket cost associated with one educational seminar per year that is designed to educate directors on their obligations as directors, best practices in corporate governance, or the skills necessary to be more effective directors.

______________________________________________________________________________

TRAVEL EXPENSE REIMBURSEMENT

______________________________________________________________________________

All directors will receive reimbursement for reasonable out-of-pocket travel expenses (e.g. airfare, hotel, rental car and meals) incurred in connection with meetings and educational seminars upon providing receipts.

______________________________________________________________________________

RETAINER AND REIMBURSEMENT PAYMENT

______________________________________________________________________________

All retainers and expense reimbursements are typically paid by Plexus quarterly at the time of quarterly Board meetings.

Document

Exhibit 31.1

CERTIFICATION

I, Todd P. Kelsey, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Plexus Corp.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 4, 2022

/s/ Todd P. Kelsey
Todd P. Kelsey
Chief Executive Officer

Document

Exhibit 31.2

CERTIFICATION

I, Patrick J. Jermain, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Plexus Corp.;

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 4, 2022

/s/ Patrick J. Jermain
Patrick J. Jermain
Executive Vice President and Chief Financial Officer

Document

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Plexus Corp. (the “Company”) on Form 10-Q for the fiscal quarter ended January 1, 2022, as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Todd P. Kelsey, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Todd P. Kelsey
Todd P. Kelsey
Chief Executive Officer
February 4, 2022

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Plexus Corp. and will be retained by Plexus Corp. and furnished to the Securities and Exchange Commission or its staff upon request.

Document

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Plexus Corp. (the “Company”) on Form 10-Q for the fiscal quarter ended January 1, 2022, as filed with the Securities and Exchange Commission on or about the date hereof (the “Report”), I, Patrick J. Jermain, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Patrick J. Jermain
Patrick J. Jermain
Executive Vice President and Chief Financial Officer
February 4, 2022

Document

										Exhibit 99.1
Return on Invested Capital ("ROIC") and Economic Return Calculations GAAP to non-GAAP reconciliation (dollars in thousands):
	Three Months Ended				Twelve Months Ended				Three Months Ended
		Jan 2,				Oct 2,				Jan 2,
		2022				2021				2021
Operating income, as reported		$	30,473			$	176,268			$	46,866
Restructuring and other charges	+	2,021			+	3,267			+	—
Adjusted operating income		32,494				179,535				46,866
	x	4							x	4
Adjusted annualized operating income		$	129,976			$	179,535			$	187,464
Adjusted effective tax rate	x	13		%	x	13		%	x	13		%
Tax impact		$	16,897			$	23,340			$	24,370
Adjusted operating income (tax effected)		$	113,079			$	156,195			$	163,094
Average invested capital		$	1,135,312			$	1,014,742			$	1,002,087
ROIC		10.0		%		15.4		%		16.3		%
WACC		9.3		%		8.1		%		8.1		%
Economic Return		0.7		%		7.3		%		8.2		%
	January 2,		October 2,		July 3,		April 3,		January 2,		October 3,
---	---	---	---	---	---	---	---	---	---	---	---	---
	2022		2021		2021		2021		2021		2020
Equity	$	1,044,095	$	1,028,232	$	1,020,450	$	1,013,952	$	1,006,959	$	977,480
Plus:
Debt and finance lease obligations - current	151,417		66,313		60,468		50,229		148,408		146,829
Operating lease obligations - current (1)	9,507		9,877		9,130		9,314		9,351		7,724
Debt and finance lease obligations - long-term	187,075		187,033		187,690		188,730		188,148		187,975
Operating lease obligations - long-term	36,343		37,970		33,193		34,751		37,052		36,779
Less:
Cash and cash equivalents	(217,067)		(270,172)		(303,255)		(294,370)		(356,724)		(385,807)
	$	1,211,370	$	1,059,253	$	1,007,676	$	1,002,606	$	1,033,194	$	970,980
(1)	Included in other accrued liabilities on the Condensed Consolidated Balance Sheets.
---	---

10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

For the quarterly period ended January 1, 2022

For the transition period from ______ to ______

Commission File Number 001-14423

PLEXUS CORP.

One Plexus Way

Neenah, Wisconsin 54957

Telephone Number (920) 969-6000

PLEXUS CORP.

TABLE OF CONTENTS

January 1, 2022

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PLEXUS CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Unaudited

The accompanying notes are an integral part of these condensed consolidated financial statements.

PLEXUS CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

Unaudited

The accompanying notes are an integral part of these condensed consolidated financial statements.

PLEXUS CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

Unaudited

The accompanying notes are an integral part of these condensed consolidated financial statements.

PLEXUS CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Unaudited

The accompanying notes are an integral part of these condensed consolidated financial statements.

PLEXUS CORP. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED JANUARY 1, 2022 AND JANUARY 2, 2021

Unaudited

Basis of Presentation:

Recently Issued Accounting Pronouncements Not Yet Adopted:

Fair Value Measurements:

Significant Judgments

Contract Costs

Disaggregated Revenue

Contract Balances

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

"SAFE HARBOR" CAUTIONARY STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995:

OVERVIEW

COVID-19 Update

RESULTS OF OPERATIONS

LIQUIDITY AND CAPITAL RESOURCES

DISCLOSURE ABOUT CRITICAL ACCOUNTING POLICIES

NEW ACCOUNTING PRONOUNCEMENTS

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 4. CONTROLS AND PROCEDURES

PART II. OTHER INFORMATION

ITEM 1A. Risk Factors

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

ITEM 6. EXHIBITS

SIGNATURES

For the transition period from to